Home HOME Acta Virologica 2022 Acta Virologica Vol.66, No.4, p. 352 – 359, 2022

Journal info

Founded: 1957
ISSN 0001-723X
E-ISSN 1336-2305

Published in English

Impact Factor = 1.82

Aims and Scope
Editorial Info

Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Acta Virologica Vol.66, No.4, p. 352 – 359, 2022

Title: Induction of immunogenic response in Balb/c mice by virus-like particles designed using the influenza neuraminidase, hemagglutinin and matrix proteins
Author: Anitha Jagadesh, Piya Paul Mudgal, Sudheesh N, Jayesh Mudgal, Anup Jayaram

Abstract: Influenza is a vaccine-preventable disease, however, vaccine production confronts the greatest challenge due to the annual emergence of mutated or newer subtypes of the influenza virus. Virus-like particles (VLPs) are the next generation vaccines trending the research domain. Several research groups have highlighted the usefulness of neuraminidase (NA) as a vaccine antigen. VLPs incorporating consistent amounts of NA are designed and tested for immunogenic potential. In this study, influenza VLPs containing hemagglutinin (HA), NA (N1 and N2), and matrix (M) proteins were designed and tested for immunogenicity in Balb/c mice. Two different concentrations of VLPs (5 µg or 10 µg) with and without 15 µg Quil-A adjuvant were injected to mice. VLPs at the 10 µg concentration administered in combination with 15 µg Quil-A adjuvant were found to induce good anti-NA and anti-HA antibody responses. The induction of immune response in mice supports the hypothesis that VLP-based vaccines are promising candidates for future vaccines.

Keywords: influenza; VLP; Quil-A adjuvant; immunogenicity; mouse model
Published online: 09-Dec-2022
Year: 2022, Volume: 66, Issue: 4 Page From: 352, Page To: 359

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.